1. 1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial. (13th November 2020) Authors: Ledermann, J; Colombo, N; Oza, A; Fujiwara, K; Birrer, MJ; Randall, L; Poddubskaya, E; Scambia, G; Shparyk, YV; Lim, MC; Lim, MC; Sohn, J; Yonemori, K; Stewart, RA; Zhang, X; Perkins Smith, J; Linn, C; Monk, BJ Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. (2nd May 2019) Authors: Colombo, N; Sessa, C; du Bois, A; Ledermann, J; McCluggage, W G; McNeish, I; Morice, P; Pignata, S; Ray-Coquard, I; Vergote, I; Baert, T; Belaroussi, I; Dashora, A; Olbrecht, S; Planchamp, F; Querleu, D Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Issue 4 (2nd May 2019) Authors: Colombo, N; Sessa, C; Bois, A du; Ledermann, J; McCluggage, WG; McNeish, I; Morice, P; Pignata, S; Ray-Coquard, I; Vergote, I; Baert, T; Belaroussi, I; Dashora, A; Olbrecht, S; Planchamp, F; Querleu, D Journal: International journal of gynecological cancer Issue: Volume 29:Issue 4(2019) Page Start: 728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Issue 4 (7th May 2019) Authors: Colombo, N; Sessa, C; Bois, A du; Ledermann, J; McCluggage, WG; McNeish, I; Morice, P; Pignata, S; Ray-Coquard, I; Vergote, I; Baert, T; Belaroussi, I; Dashora, A; Olbrecht, S; Planchamp, F; Querleu, D Journal: International journal of gynecological cancer Issue: Volume 29:Issue 4(2019) Page Start: 728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2nd May 2019) Authors: Colombo, N; Sessa, C; du Bois, A; Ledermann, J; McCluggage, W G; McNeish, I; Morice, P; Pignata, S; Ray-Coquard, I; Vergote, I; Baert, T; Belaroussi, I; Dashora, A; Olbrecht, S; Planchamp, F; Querleu, D Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Guidelines for resection of colorectal cancer liver metastases. (11th July 2006) Authors: Garden, O J; Rees, M; Poston, G J; Mirza, D; Saunders, M; Ledermann, J; Primrose, J N; Parks, R W Journal: Gut Issue: Volume 55(2006)Supplement 3 Page Start: iii1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. (1st November 2019) Authors: Mirza, MR; Dørum, A; Benigno, B; Mahner, S; Bessette, P; Bover Barcelo, IM; Berton, D; Ledermann, J; Rimel, BJ; Herrstedt, J; Lau, S; Canzler, U; Palacio Vázquez, I; Kalbacher, E; Buscema, J; Lorusso, D; Debruyne, P; Bruchim, I; Guo, W; Gupta, D Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety and dose modification for patients receiving niraparib. (13th August 2018) Authors: Berek, J S; Matulonis, U A; Peen, U; Ghatage, P; Mahner, S; Redondo, A; Lesoin, A; Colombo, N; Vergote, I; Rosengarten, O; Ledermann, J; Pineda, M; Ellard, S; Sehouli, J; Gonzalez-Martin, A; Berton-Rigaud, D; Madry, R; Reinthaller, A; Hazard, S; Guo, W Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 859 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Safety and dose modification for patients receiving niraparib. (14th May 2018) Authors: Berek, J S; Matulonis, U A; Peen, U; Ghatage, P; Mahner, S; Redondo, A; Lesoin, A; Colombo, N; Vergote, I; Rosengarten, O; Ledermann, J; Pineda, M; Ellard, S; Sehouli, J; Gonzalez-Martin, A; Berton-Rigaud, D; Madry, R; Reinthaller, A; Hazard, S; Guo, W Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1784 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The European Network of Gynecological Oncological Trial Groups. (January 2012) Authors: Vergote, I; Pujade-Lauraine, E; Pignata, S; Kristensen, GB; Ledermann, J; Casado, A; Sehouli, J; Mirza, M; Fossati, R; Marth, C; Ottevanger, N; Del Campo, J; Siddiqui, N; Calvert, P; Bamias, A; Tulunay, G; Van der Zee, AGJ; du Bois, A Journal: Clinical investigation Issue: Volume 2:Number 1(2012) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗